The Center for Computational Imaging and Personalized Diagnostics’ Anant Madabhushi, the center director, and Pranjal Vaidya, a PhD candidate, with collaborators Kaustav Bera and Vamsidhar Velcheti were awarded US Patent No. 10,839,513, titled “Distinguishing hyperprogression from other response patterns to PD1/PD-L1 inhibitors in non-small cell lung cancer with pre-therapy radiomic features.” 

Shortly following this award, CCIPD researchers also were awarded US Patent No. 10,846,367, titled “Predicting recurrence in early stage non-small cell lung cancer (NSCLC) with integrated radiomic and pathomic features.” CCIPD co-inventors for this patent include Madabhushi, Xiangxue Wang and Vaidya.

(From The Daily, 12/18/2020)